You are here

  • Home
  • Archive
  • Volume 9, Issue 6
  • Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI

Article info

Article menu

Download PDFPDF

XML
Urology
Protocol
Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI

Authors

  • Tobias Nordström Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden Department of Clinical Sciences at Danderyd Hospital, Karolinska Institutet, Solna, Sweden PubMed articlesGoogle scholar articles
  • Fredrik Jäderling Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden Department of Diagnostic Radiology, Karolinska University Hospital, Stockholm, Sweden PubMed articlesGoogle scholar articles
  • Stefan Carlsson Patient area Pelvic Cancer, Theme Cance Karolinska University Hospital Solna, Stockholm, Sweden PubMed articlesGoogle scholar articles
  • Markus Aly Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden Patient area Pelvic Cancer, Theme Cance Karolinska University Hospital Solna, Stockholm, Sweden PubMed articlesGoogle scholar articles
  • Henrik Grönberg Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden PubMed articlesGoogle scholar articles
  • Martin Eklund Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden PubMed articlesGoogle scholar articles
  1. Correspondence to Tobias Nordström; tobias.nordstrom{at}ki.se
View Full Text

Citation

Nordström T, Jäderling F, Carlsson S, et al
Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI
BMJ Open 2019;9:e027816. doi: 10.1136/bmjopen-2018-027816

Publication history

  • Received November 20, 2018
  • Revised May 13, 2019
  • Accepted May 14, 2019
  • First published June 14, 2019.
Online issue publication 
August 05, 2023
Previous versions
Review history

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.